Comparing direct acting antivirals for hepatitis C using observational data – Why and how?

The World Health Organisation's goal of hepatitis C virus (HCV) elimination by 2030 will require lower drug prices. Estimates of comparative efficacy promote competition between pharmaceutical companies but direct acting antivirals have been approved for the treatment of HCV without comparative...

Descripción completa

Detalles Bibliográficos
Autores principales: Young, Jim, Wong, Stanley, Janjua, Naveed Z., Klein, Marina B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507378/
https://www.ncbi.nlm.nih.gov/pubmed/32894643
http://dx.doi.org/10.1002/prp2.650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507378/
https://www.ncbi.nlm.nih.gov/pubmed/32894643
http://dx.doi.org/10.1002/prp2.650

Ejemplares similares